LATEST NEWS

Category Archives: Company

Forendo Pharma signs important License and Collaboration Deal with Leading Pharma Company

Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women’s health, today announces signing of a License and Collaboration Agreement with Novartis. The joint research collaboration is aimed at the identification of novel drugs for the treatment of chronic liver diseases. Novartis receives a worldwide exclusive license to drug candidates generated […]

Endometriosis program Phase 1b Proof of Mechanism Study initiated

Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women’s health, today announces initiation of dosing in a Phase 1b clinical study in its lead endometriosis program with the aim to demonstrate Proof of Mechanism. The novel oral compound, FOR-6219, is a HSD17B1 inhibitor aiming to reduce estrogen production locally in […]

Sunstone Life Science Ventures joins Forendo Pharma Investor Syndicate

Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women’s health, today announces that Sunstone Life Science Ventures has made a €5 million investment in Forendo. Sunstone joins the existing international investor syndicate comprising Novo Seeds, Karolinska Development, Innovestor, Novartis Venture Fund, M Ventures and Vesalius Biocapital III. Claus Andersson, General […]

Positive Phase 1a Results of FOR-6219

Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women’s health, today announces that it has successfully completed Phase 1a study of its lead program FOR-6219, a novel, tissue specific treatment of endometriosis. FOR-6219 was found to be safe and well tolerated, with good pharmacokinetics at the doses tested. Endometriosis is […]

Vesalius Biocapital III Partners joins Forendo Pharma Investor Syndicate

Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women’s health, today announces that it has raised an additional €4 million of funding from Vesalius Biocapital III Partners (Vesalius III). This is in addition to the €12 million Series A financing in 2014 and €5,7 million R&D loans granted by Business […]

Forendo receives clinical trial authorization to initiate phase I study

Forendo Pharma has received clinical trial authorization (CTA) from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to commence a study for its lead program, FOR-6219. Endometriosis is a chronic condition that affects up to 10% of women in reproductive age and causes repeated pain symptoms, infertility and impaired quality of life. Currently available […]

Forendo receives €3 million loan from Business Finland

Business Finland grants Forendo Pharma a €3 million R&D loan for the development of a new drug for endometriosis treatment. The funding from Business Finland will enable Forendo to strengthen its women’s health portfolio, by progressing its early stage DUAL HSD Inhibitor program, targeting broader gynaecological conditions, including endometriosis, into preclinical development. The DUAL HSD […]

David Colpman joins the Board of Directors of Forendo Pharma

Forendo Pharma, a drug development company developing novel oral treatments for endometriosis patients, today announces the appointment of David Colpman as a non-executive director to its Board of Directors. David brings with him an impressive career of more than 25 years in pharma and biotech business development and strategy. His previous roles include Head of […]

Scrip Pharmaceuticals profiles Forendo Pharma

Forendo Pharma CEO, Risto Lammintausta, was interviewed by Scrip Pharmaceuticals for an Emerging Company Profile section of the publication: “Forendo Pharma: Tackling The Endometriosis Challenge”. Get pdf version of the Scrip article by clicking here SCRIP is a leading source of news and strategic analysis for the global pharmaceutical industry, with over 14,000 registered users […]

Forendo Pharma nominates world class scientific advisory board and elects Professor Linda Giudice as the chairperson

Forendo Pharma, a drug development company developing novel oral treatments for endometriosis patients, announces the nomination of its Scientific Advisory Board today. Forendo is developing tissue-specific hormone inhibitors to rebalance local estrogen metabolism in endometrial tissues. The key differentiator of the company’s lead HSD17B1 inhibitor compared to other drug treatments is the ability to act […]